Nabriva Therapeutics AG COO Steven Gelone's 2021 pay jumps 34% to $1.5M
Nabriva Therapeutics AG reports 2021 executive compensation
By ExecPay News
Published: July 11, 2022
Nabriva Therapeutics AG reported fiscal year 2021 executive compensation information on July 11, 2022.
In 2021, three executives at Nabriva Therapeutics AG received on average a compensation package of $1.1M, a 22% decrease compared to previous year.
Average pay of disclosed executives at Nabriva Therapeutics AG
Steven Gelone, Chief Operating Officer, received $1.5M in total, which increased by 34% compared to 2020. 40% of Gelone's compensation, or $611K, was in stock awards. Gelone also received $225K in bonus, $192K in non-equity incentive plan, $501K in salary, as well as $14K in other compensation.
Theodore Schroeder, Chief Executive Officer, received a compensation package of $1.2M, which decreased by 25% compared to previous year. 48% of the compensation package, or $594K, was in salary.
Daniel Dolan, Chief Financial Officer, earned $501K in 2021.
Related executives
You may also like
Source: SEC filing on July 11, 2022.